These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23900878)

  • 21. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.
    Dieterle W; Mann J; Kutz K
    J Clin Pharmacol; 2004 Jan; 44(1):59-66. PubMed ID: 14681342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
    Bruderer S; Aänismaa P; Homery MC; Häusler S; Landskroner K; Sidharta PN; Treiber A; Dingemanse J
    AAPS J; 2012 Mar; 14(1):68-78. PubMed ID: 22189899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.
    Sidharta PN; Dietrich H; Dingemanse J
    Clin Drug Investig; 2014 Aug; 34(8):545-52. PubMed ID: 24861134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
    Dieterle W; Mann J; Kutz K
    Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.
    Bruderer S; Marjason J; Sidharta PN; Dingemanse J
    Pharmacology; 2013; 91(5-6):331-8. PubMed ID: 23817130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects.
    Issac M; Dingemanse J; Sidharta PN
    J Clin Pharmacol; 2017 Aug; 57(8):997-1004. PubMed ID: 28378883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macitentan does not interfere with hepatic bile salt transport.
    Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
    J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
    Sen S; Chen S; Feng B; Iglarz M; Chakrabarti S
    Life Sci; 2012 Oct; 91(13-14):658-68. PubMed ID: 22525377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
    Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
    J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
    Herbert S; Gin-Sing W; Howard L; Tulloh RMR
    Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
    Sidharta PN; Lindegger N; Ulč I; Dingemanse J
    J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
    Clozel M
    Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects.
    Hurst N; Pellek M; Dingemanse J; Sidharta PN
    J Clin Pharmacol; 2016 Jun; 56(6):669-74. PubMed ID: 26381054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
    J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.
    Cutler DL; Tendolkar A; Grachev ID
    J Clin Pharm Ther; 2012 Oct; 37(5):578-87. PubMed ID: 22676397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.